Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, touches on the Phase II ELARA trial which looks at the efficacy and safety of tisagenlecleucel (tisa-cel) in patients with relapsed follicular lymphoma (NCT03568461). Dr Riedell emphasizes the encouraging results of the trial with a favourable complete response rate observed. However, follow-up is ideal to understand the long-term outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.